Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The OCTOVA study has completed recruitment and will now begin its follow-up phase.

OCTOVA logo

Breaking news - the OCTOVA trial successfully completed patient recruitment on 02Jan2020!

"Reaching our recruitment target of 138 patients has taken 3.5 years and has been a great team effort. We would like to say a big thank you to all the investigators and patients at our participating sites."

OCTOVA is a randomised trial comparing the activity of the PARP inhibitor, olaparib, alone or in combination with cediranib, with weekly paclitaxel in women with relapsed ovarian cancer. Women with or without a BRCA mutation and those who have previously received PARP inhibitors have been included in the trial. The associated sample collection will permit future research to analyse further who responds to PARP inhibitors alone and in combination.

The trial will also compare patient reported outcomes to examine the quality of life in women taking oral daily tablets at home versus weekly infusions in hospital. It is expected the primary endpoint analysis will take place in 2020 and a link to the results will be posted on the OCTOVA website once available.

Similar stories

WHiTE Four trial results!

OCTRU

The WHiTE Four trial has now published its results in The Bone & Joint journal.

FUTURE GB Trial opens to recruitment!

OCTRU

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

ARCADIAN trial opens to recruitment!

OCTRU

The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

HOPE-e study resumes recruitment of women with painful osteoarthritis in the hand

Main OCTRU

Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.

HUSH trial opens to recruitment!

OCTRU

The HUSH trial has received OCTRU Green Light approval and is now open to recruitment!

Oxford researchers start new trial on the use of anti-TNF to treat Covid-19 in care homes

Main OCTRU Trials

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.